Phase 2 randomized, double-blinded, placebo-controlled, dose-finding clinical study of DARE-VVA1
Latest Information Update: 12 Dec 2023
At a glance
- Drugs Tamoxifen (Primary)
- Indications Atrophic vaginitis; Dyspareunia
- Focus Therapeutic Use
- 07 Dec 2023 According to a Dare Bioscience media release, the company is not planning to commence the study until after securing additional capital.
- 07 Dec 2023 According to a Dare Bioscience media release, the U.S. Food and Drug Administration (FDA) has cleared an new drug (IND) application for DARE-VVA1.
- 13 Jun 2023 New trial record